How many Upadacitinib clinical trials are there?

103 Upadacitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 32 are actively recruiting participants. 38 are marked completed.

Are Upadacitinib clinical trials recruiting in 2026?

Yes — 32 Upadacitinib trials are actively recruiting in 2026, with 225 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Upadacitinib being studied for?

Upadacitinib is being studied for Atopic Dermatitis, Rheumatoid Arthritis, Ulcerative Colitis (UC), Crohn's Disease, Psoriatic Arthritis and 74 more. The trials are grouped by indication on this page.

What phase is Upadacitinib in?

Upadacitinib clinical trials span 15 Phase 4, 45 Phase 3, 15 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Upadacitinib clinical trials?

The lead sponsor across the most Upadacitinib trials is AbbVie, with 33 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Upadacitinib Clinical Trials (2026): 103 Studies for Atopic Dermatitis & Rheumatoid Arthritis

Creator: Hipa.ai Research
Published: 2026-05-08T19:18:19.027Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

103 Upadacitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 53 indications (including Atopic Dermatitis & Rheumatoid Arthritis) and 36,035 total planned enrollment. 45 Phase 3 Upadacitinib trials and 15 Phase 2, 15 Phase 4 are listed. 44 Upadacitinib clinical trials are actively recruiting at 225 U.S. sites across 38 states. Most recent activity: NCT06332534 (Dec 2034).

Where to Participate: All Upadacitinib Trial Sites in the U.S. (225 sites across 38 states)

Every actively recruiting Upadacitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Cahaba Dermatology & Skin Health Center /ID# 254876	Birmingham35244	NCT05889182	Map
AL	Cahaba Dermatology & Skin Health Center /ID# 263855	Birmingham35244	NCT06389136	Map
AZ	Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564	Fountain Hills85268	NCT05889182	Map
AZ	Medical Dermatology Specialists /ID# 254226	Phoenix85006	NCT05889182	Map
AZ	Phoenix Children's Hospital /ID# 253403	Phoenix85016-7710	NCT05609630	Map
AZ	Mayo Clinic - Scottsdale /ID# 254388	Scottsdale85259-5452	NCT05889182	Map
AZ	One Of A Kind Clinical Research Center - Scottsdale /ID# 278675	Scottsdale85253	NCT06389136	Map
AZ	Banner University Medicine Dermatology /ID# 255853	Tucson85718-1407	NCT05889182	Map
AR	Clinical Trials Institute - Northwest Arkansas /ID# 254924	Fayetteville72703	NCT05889182	Map
AR	Clinical Trials Institute - Northwest Arkansas /ID# 267290	Fayetteville72703	NCT06389136	Map
AR	Burke Pharmaceutical Research /ID# 254238	Hot Springs71913-6404	NCT05889182	Map
AR	Applied Research Center Of Arkansas /ID# 268547	Little Rock72205	NCT06461897	Map
AR	Arkansas Research Trials /ID# 254233	North Little Rock72217	NCT05889182	Map
AR	NW Arkansas Clinical Trials Center /ID# 254311	Rogers72758	NCT05889182	Map
CA	Private Practice - Dr. Tooraj Raoof /ID# 254374	Encino91436	NCT05889182	Map
CA	Private Practice - Dr. Tooraj Raoof /ID# 263849	Encino91436	NCT06389136	Map
CA	First OC Dermatology /ID# 259220	Fountain Valley92708	NCT06012240	Map
CA	First OC Dermatology /ID# 263349	Fountain Valley92708	NCT06389136	Map
CA	NorCal Medical Research /ID# 278397	Greenbrae94904	NCT06389136	Map
CA	Marvel Clinical Research /ID# 276228	Huntington Beach92647	NCT05889182	Map
CA	Dermatology Research Associates /ID# 254846	Los Angeles90045	NCT05889182	Map
CA	Dermatology Research Associates /ID# 258033	Los Angeles90045	NCT06012240	Map
CA	Allergy & Asthma Associates of Southern California - Mission Viejo /ID# 266574	Mission Viejo92691	NCT06389136	Map
CA	UCSF Benioff Children's Hospital - Oakland /ID# 262217	Oakland94609	NCT06332534	Map
CA	Dermatologist Medical Group of North County- Profound Research /ID# 266512	Oceanside92056	NCT06389136	Map
CA	Lucile Packard Children's Hospital /ID# 262193	Palo Alto94304	NCT06332534	Map
CA	Stanford University School of Medicine - Palo Alto /ID# 269622	Palo Alto94304	NCT06461897	Map
CA	Comprehensive Dermatology Center of Pasadena /ID# 281014	Pasadena91105	NCT06389136	Map
CA	Stanford University School of Medicine - Redwood City /ID# 263776	Redwood City94063	NCT06389136	Map
CA	NorCal Clinical Research /ID# 274219	Rocklin95765	NCT05889182	Map
CA	Integrative Skin Science and Research /ID# 254930	Sacramento95815	NCT05889182	Map
CA	Integrative Skin Science and Research /ID# 258114	Sacramento95815	NCT06012240	Map
CA	Integrative Skin Science and Research /ID# 264537	Sacramento95815	NCT06389136	Map
CA	Integrative Skin Science and Research /ID# 265108	Sacramento95815	NCT06461897	Map
CA	University of California Davis Health /ID# 254229	Sacramento95817	NCT05889182	Map
CA	University of California Davis Health /ID# 258112	Sacramento95817	NCT06012240	Map
CA	Laura Rodriguez Research Institute	San Diego92101	NCT06928272	Map
CA	West Dermatology La Jolla /ID# 265014	San Diego92121	NCT06389136	Map
CA	Clinical Trials Research Institute /ID# 254466	Thousand Oaks91320-2130	NCT05889182	Map
CA	Clinical Trials Research Institute /ID# 258021	Thousand Oaks91320-2130	NCT06012240	Map
CA	Clinical Trials Research Institute /ID# 263846	Thousand Oaks91320	NCT06389136	Map
CO	Children's Hospital Colorado - Aurora /ID# 262207	Aurora80045	NCT06332534	Map
CO	Peak Gastroenterology Associates	Colorado Springs80907	NCT06227910	Map
CT	UConn Health Main /ID# 254507	Farmington06032	NCT05889182	Map
CT	Connecticut Children's Medical Center - Hartford /ID# 262256	Hartford06106	NCT06332534	Map
CT	Yale University School of Medicine /ID# 254586	New Haven06510	NCT05889182	Map
CT	Yale University School of Medicine /ID# 263836	New Haven06510	NCT06389136	Map
DC	Childrens National Medical Center /ID# 253344	Washington D.C.20010-2916	NCT05609630	Map
FL	Skin Care Research Boca Raton /ID# 253814	Boca Raton33486-2269	NCT05889182	Map
FL	Skin Care Research Boca Raton /ID# 258012	Boca Raton33486-2269	NCT06012240	Map
FL	Skin Care Research Boca Raton /ID# 263733	Boca Raton33486-2269	NCT06389136	Map
FL	Apex Clinical Trials /ID# 255756	Brandon33511	NCT05889182	Map
FL	TrueBlue Clinical Research - Brandon /ID# 265037	Brandon33511	NCT06389136	Map
FL	Florida Academic Dermatology Center /ID# 254011	Coral Gables33134-5755	NCT05889182	Map
FL	Pediatric Skin Research /ID# 266308	Coral Gables33146	NCT06461897	Map
FL	Life Clinical Trials - Coral Springs /ID# 267195	Coral Springs33071	NCT06389136	Map
FL	Dermatology Associates of the Palm Beaches /ID# 275950	Delray Beach33445	NCT05889182	Map
FL	FXM Clinical Research Ft. Lauderdale /ID# 280911	Fort Lauderdale33308	NCT06389136	Map
FL	Skin Care Research - Hollywood /ID# 254508	Hollywood33021-6748	NCT05889182	Map
FL	Skin Care Research - Hollywood /ID# 259210	Hollywood33021-6748	NCT06012240	Map
FL	Skin Care Research - Hollywood /ID# 263739	Hollywood33021-6748	NCT06389136	Map
FL	GSI Clinical Research, LLC /ID# 259352	Margate33063	NCT06012240	Map
FL	GSI Clinical Research, LLC /ID# 263760	Margate33063-7011	NCT06389136	Map
FL	Life Clinical Trials /ID# 258613	Margate33063	NCT05889182	Map
FL	FAX Pharma Clinical Research /ID# 280915	Miami33146	NCT06389136	Map
FL	International Dermatology Research /ID# 264961	Miami33144	NCT06389136	Map
FL	Lenus Research and Medical Group /ID# 259356	Miami33172	NCT06012240	Map
FL	Lenus Research and Medical Group /ID# 263779	Miami33172	NCT06389136	Map
FL	Research Associates of South Florida /ID# 267291	Miami33134	NCT06389136	Map
FL	Sullivan Dermatology /ID# 263537	Miami33162	NCT06389136	Map
FL	Fxm Clinical Research - Miramar /ID# 280934	Miramar33027	NCT06389136	Map
FL	Global Clinical Professionals (GCP) /ID# 266474	St. Petersburg33705	NCT06389136	Map
FL	Advanced Clinical Research Institute - Tampa /ID# 259204	Tampa33607	NCT06012240	Map
FL	Advanced Clinical Research Institute /ID# 253746	Tampa33607	NCT05889182	Map
FL	Alliance Clinical Research of Tampa /ID# 264531	Tampa33615	NCT06389136	Map
FL	Skin Care Research - Tampa /ID# 256440	Tampa33607-6438	NCT05889182	Map
FL	Skin Care Research - Tampa /ID# 263750	Tampa33607-6438	NCT06389136	Map
FL	Encore Medical Research - Weston /ID# 278491	Weston33331	NCT06389136	Map
GA	Centricity Research /ID# 255470	Columbus31904-2954	NCT05889182	Map
GA	Centricity Research Columbus Dermatology /ID# 266529	Columbus31904	NCT06389136	Map
GA	Cleaver Medical Group Dermatology /ID# 263788	Dawsonville30534	NCT06389136	Map
GA	Aeroallergy Research Laboratory /ID# 267247	Savannah31406	NCT06461897	Map
ID	Treasure Valley Medical Research /ID# 255208	Boise83706	NCT05889182	Map
ID	Treasure Valley Medical Research /ID# 263738	Boise83706	NCT06389136	Map
ID	Treasure Valley Medical Research /ID# 266838	Boise83706	NCT06461897	Map
IL	DeNova Research /ID# 254372	Chicago60610	NCT05889182	Map
IL	DeNova Research /ID# 264513	Chicago60610	NCT06389136	Map
IL	Northwestern University Department of Dermatology	Chicago60611	NCT06684522	Map
IL	Northwestern University Feinberg School of Medicine /ID# 254503	Chicago60611-2927	NCT05889182	Map
IL	Northwestern University Feinberg School of Medicine /ID# 264983	Chicago60611-2927	NCT06389136	Map
IL	Northwestern University Feinberg School of Medicine /ID# 265117	Chicago60611-2927	NCT06461897	Map
IL	Acpru /Id# 279285	Grayslake60030	NCT07425899	Map
IL	Sneeze Wheeze & Itch Associates /ID# 267238	Normal61761	NCT06461897	Map
IL	OSF St. Francis Medical Center /ID# 262192	Peoria61637-0001	NCT06332534	Map
IL	NorthShore University HealthSystem - Skokie /ID# 254389	Skokie60077	NCT05889182	Map
IN	Dawes Fretzin, LLC /ID# 254390	Indianapolis46256	NCT05889182	Map
IN	Dawes Fretzin, LLC /ID# 265097	Indianapolis46256	NCT06461897	Map
IN	Indiana University Health Riley Hospital for Children /ID# 262215	Indianapolis46202	NCT06332534	Map
IN	Indiana University Health University Hospital /ID# 259827	Indianapolis46202	NCT06012240	Map
IN	Options Research Group /ID# 254537	West Lafayette47906	NCT05889182	Map
IN	Options Research Group /ID# 264564	West Lafayette47906	NCT06389136	Map
KS	U.S. Dermatology Partners Leawood /ID# 255838	Leawood66211-1453	NCT05889182	Map
KY	Equity Medical, LLC /ID# 268270	Bowling Green42104	NCT06461897	Map
KY	Equity Medical, LLC /ID# 271140	Bowling Green42104	NCT05889182	Map
LA	Tulane University School of Medicine /ID# 259799	New Orleans70112	NCT06012240	Map
MD	Maryland Allergy & Asthma Center /ID# 268032	Lanham20706	NCT06461897	Map
MD	DermAssociates - Rockville /ID# 266457	Rockville20850	NCT06461897	Map
MA	Beth Israel Deaconess Medical Center /ID# 253811	Boston02215-5400	NCT05889182	Map
MA	Boston Children's Hospital /ID# 262191	Boston02115	NCT06332534	Map
MA	Boston Specialists /ID# 265810	Boston02111-1901	NCT06389136	Map
MA	Massachusetts General Hospital /ID# 261093	Boston02114	NCT05889182	Map
MA	Beacon Clinical Research /ID# 263843	Quincy02169	NCT06389136	Map
MA	Beacon Clinical Research, LLC /ID# 254419	Quincy02169	NCT05889182	Map
MA	UMass Memorial Medical Center /ID# 258839	Worcester01605	NCT05889182	Map
MI	University of Michigan	Ann Arbor48109	NCT05867329	Map
MI	University of Michigan	Ann Arbor48109	NCT07258771	Map
MI	The Derm Institute Of West Michigan /ID# 275948	Caledonia49316	NCT05889182	Map
MI	Hamzavi Dermatology - Canton /ID# 275856	Canton48187	NCT05889182	Map
MI	Clarkston Dermatology /ID# 258018	Clarkston48346	NCT06012240	Map
MI	Michigan Center for Medical Research /ID# 275860	Clarkston48346	NCT05889182	Map
MI	Henry Ford Medical Center - New Center One /ID# 263522	Detroit48202-3046	NCT06389136	Map
MI	Michigan Dermatology Institute /ID# 254468	Waterford48328	NCT05889182	Map
MN	MNGI Digestive Health, P. A. /ID# 262204	Minneapolis55413-2195	NCT06332534	Map
MO	Cleaver Dermatology /ID# 254391	Kirksville63501-5362	NCT05889182	Map
MO	Dermatology and Skin Center of Lees Summit /ID# 257546	Lee's Summit64064-2301	NCT05889182	Map
MO	MediSearch Clinical Trials /ID# 254392	Saint Joseph64506	NCT05889182	Map
MO	MediSearch Clinical Trials /ID# 263579	Saint Joseph64506	NCT06389136	Map
MO	SSM Health Saint Louis University Hospital /ID# 256437	St Louis63104	NCT05889182	Map
MO	Washington University School of Medicine - St. Louis /ID# 254506	St Louis63130	NCT05889182	Map
MO	Washington University School of Medicine - St. Louis /ID# 268545	St Louis63130	NCT06461897	Map
NE	Physician Research Collaboration, LLC /ID# 263583	Lincoln68516	NCT06389136	Map
NE	Skin Specialists /ID# 259237	Omaha68144	NCT06012240	Map
NE	Skin Specialists /ID# 263345	Omaha68144	NCT06389136	Map
NE	Skin Specialists /ID# 266331	Omaha68144	NCT06461897	Map
NV	Las Vegas Dermatology /ID# 265801	Las Vegas89144	NCT06389136	Map
NV	Las Vegas Dermatology /ID# 272421	Las Vegas89144	NCT05889182	Map
NV	Las Vegas Dermatology /ID# 279317	Las Vegas89144	NCT06012240	Map
NV	Vivida Dermatology- Flamingo /ID# 254227	Las Vegas89119-5190	NCT05889182	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 254410	Reno89509	NCT05889182	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 259208	Reno89509	NCT06012240	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 263771	Reno89509	NCT06389136	Map
NH	Dartmouth Hitchcock Medical Center - Old Etna Road /ID# 263840	Lebanon03766	NCT06389136	Map
NY	Empire Dermatology /ID# 276241	East Syracuse13057	NCT05889182	Map
NY	NorthWell Health - Dermatology /ID# 254704	New Hyde Park11042-2058	NCT05889182	Map
NY	Equity Medical /ID# 266680	New York10023-7340	NCT06012240	Map
NY	Equity Medical, LLC /ID# 265814	New York10023-7340	NCT06389136	Map
NY	Icahn School of Medicine at Mount Sinai /ID# 262216	New York10029	NCT06332534	Map
NY	Private Practice - Dr. Bobby Buka /ID# 276371	New York10012	NCT05889182	Map
NY	Sadick Research Group LLC /ID# 266790	New York10075	NCT06012240	Map
NY	Weill Cornell Medicine /ID# 265793	New York10065	NCT06389136	Map
NY	New York Medical College /ID# 253437	Valhalla10595	NCT05609630	Map
NC	Univ NC Chapel Hill /ID# 262198	Chapel Hill27514-4220	NCT06332534	Map
NC	Onsite Clinical Solutions /ID# 254854	Charlotte28277-3816	NCT05889182	Map
NC	Duke University Medical Center /ID# 256898	Durham27710	NCT05889182	Map
NC	Piedmont Plastic Surgery and Dermatology - Huntersville /ID# 266545	Huntersville28078-7961	NCT06389136	Map
OH	DOCS Clinical Research - Canal Winchester /ID# 268271	Canal Winchester43110-2069	NCT06461897	Map
OH	Apex Clinical Research Center, LLC /ID# 275956	Canton44718	NCT05889182	Map
OH	Cincinnati Childrens Hospital Medical Center /ID# 251827	Cincinnati45229	NCT05609630	Map
OH	Cleveland Clinic - Cleveland /ID# 258113	Cleveland44195	NCT06012240	Map
OH	UH Cleveland Medical Center /ID# 262188	Cleveland44106	NCT06332534	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06454188	Map
OH	ClinOhio Research Services /ID# 254851	Columbus43213-4440	NCT05889182	Map
OH	Wright State Physicians Health Center /ID# 268841	Fairborn45324	NCT06461897	Map
OH	Dermatologists of Southwest Ohio, Inc /ID# 254297	Mason45040-4520	NCT05889182	Map
OH	Dermatologists of Southwest Ohio, Inc /ID# 260116	Mason45040-4520	NCT06012240	Map
OH	Dermatology Partners - Medina /ID# 275939	Medina44256	NCT05889182	Map
OK	Lynn Institute of Oklahoma City /ID# 253791	Oklahoma City73112	NCT05889182	Map
OR	Oregon Dermatology and Research Center /ID# 258243	Portland97210	NCT06012240	Map
OR	Oregon Health and Science University	Portland97239	NCT06454188	Map
OR	Oregon Health and Science University /ID# 254929	Portland97239	NCT05889182	Map
OR	Oregon Health and Science University /ID# 263736	Portland97239	NCT06389136	Map
OR	Oregon Health and Science University /ID# 266483	Portland97239	NCT06461897	Map
OR	Randall Children's Hospital /ID# 251829	Portland97227-1654	NCT05609630	Map
PA	Penn State Milton S. Hershey Medical Center /ID# 254925	Hershey17033-2360	NCT05889182	Map
PA	Children's Hospital of Philadelphia - Main /ID# 262197	Philadelphia19104-4319	NCT06332534	Map
PA	Clinical Research of Philadelphia /ID# 264972	Philadelphia19114	NCT06389136	Map
PA	Clinical Research of Philadelphia, LLC /ID# 255308	Philadelphia19114	NCT05889182	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06454188	Map
PA	University of Pittsburgh Medical Center /ID# 264526	Pittsburgh15213	NCT06389136	Map
PA	Dermatology Associates of Plymouth Meeting /ID# 267286	Plymouth Meeting19462	NCT06389136	Map
SC	Medical University of South Carolina /ID# 263655	Charleston29425	NCT06389136	Map
SC	Medical University of South Carolina /ID# 265113	Charleston29425	NCT06461897	Map
SC	Medical University of South Carolina /ID# 272569	Charleston29425	NCT05889182	Map
SC	Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 267185	Spartanburg29307	NCT06389136	Map
SC	Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 278359	Spartanburg29307	NCT06012240	Map
SD	Health Concepts /ID# 263383	Rapid City57702	NCT06389136	Map
TN	Dermatology Associates of Knoxville /ID# 261082	Knoxville37917	NCT05889182	Map
TN	International Clinical Research - Tennessee LLC /ID# 259552	Murfreesboro37130-2450	NCT06012240	Map
TX	Arlington Research Center, Inc /ID# 253805	Arlington76011	NCT05889182	Map
TX	Arlington Research Center, Inc /ID# 258028	Arlington76011	NCT06012240	Map
TX	Arlington Research Center, Inc /ID# 263665	Arlington76011	NCT06389136	Map
TX	Arlington Research Center, Inc /ID# 266330	Arlington76011	NCT06461897	Map
TX	Bellaire Dermatology Associates /ID# 253797	Bellaire77401	NCT05889182	Map
TX	Bellaire Dermatology Associates /ID# 259360	Bellaire77401	NCT06012240	Map
TX	U.S. Dermatology Partners - Cedar Park /ID# 259367	Cedar Park78613	NCT06012240	Map
TX	Studies in Dermatology LLC /ID# 263335	Cypress77429	NCT06389136	Map
TX	Dermatology Treatment and Research Center /ID# 259357	Dallas75230	NCT06012240	Map
TX	Dermatology Treatment and Research Center /ID# 265812	Dallas75230	NCT06389136	Map
TX	HRMD Research Dallas /ID# 255256	Dallas75240-6246	NCT05889182	Map
TX	Modern Research Associates /ID# 263852	Dallas75231	NCT06389136	Map
TX	Modern Research Associates, PLLC /ID# 253810	Dallas75231	NCT05889182	Map
TX	3A Research - East location /ID# 267622	El Paso79925	NCT06461897	Map
TX	BRCR Global - Katy /ID# 267304	Katy77450	NCT06389136	Map
TX	Prime Clinical Research - Mansfield - East Broad Street /ID# 268042	Mansfield76063	NCT06461897	Map
TX	Sms Clinical Research /ID# 278676	Mesquite75149	NCT06389136	Map
TX	Texas Dermatology Research Center, LLC /ID# 254928	Plano75025	NCT05889182	Map
TX	Progressive Clinical Research - San Antonio /ID# 267262	San Antonio78229	NCT06461897	Map
TX	Southern Star Research Institute, LLC	San Antonio78229	NCT06227910	Map
TX	Texas Dermatology and Laser Specialists /ID# 267249	San Antonio78218	NCT06461897	Map
TX	Stride Clinical Research /ID# 267331	Sugar Land77479	NCT06389136	Map
TX	The Woodlands Dermatology Associates /ID# 266547	The Woodlands77380	NCT06389136	Map
TX	Dermatology Associates of Tyler /ID# 264980	Tyler75703	NCT06389136	Map
TX	Tyler Research Institute, LLC	Tyler75701	NCT06227910	Map
TX	Center for Clinical Studies Webster TX /ID# 254242	Webster77598	NCT05889182	Map
UT	Cope Family Medicine - Ogden Clinic /ID# 276227	Bountiful84010	NCT05889182	Map
UT	University of Utah /ID# 254452	Murray84107	NCT05889182	Map
UT	Jordan Valley Dermatology & Research Center /ID# 267092	South Jordan84095	NCT06461897	Map
UT	Springville Dermatology - Springville /ID# 276225	Springville84663	NCT05889182	Map
VA	University of Virginia - Dermatology /ID# 254535	Charlottesville22903	NCT05889182	Map
VA	The Education & Research Foundation, Inc. /ID# 254852	Lynchburg24501-1403	NCT05889182	Map
VA	Virginia Clinical Research /ID# 254538	Norfolk23507	NCT05889182	Map
WA	Frontier Dermatology /ID# 254554	Mill Creek98012	NCT05889182	Map
WV	West Virginia Research Institute - Morgantown /ID# 264930	Morgantown26505	NCT06389136	Map
WV	West Virginia University Hospitals /ID# 265114	Morgantown26506	NCT06461897	Map
WI	Wisconsin Medical Center /ID# 267236	Milwaukee53226	NCT06461897	Map

Upadacitinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	available	Total
Early P1	1								1
P1	3	1	1						5
P1/P2	1								1
P2			10	1		4			15
P2/P3			2						2
P3	10	11	20		2	1	1		45
P4	7		2	1		4	1		15
N/A	10	1	3			3	1	1	19

Recruiting Upadacitinib clinical trials (44)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06332534	U-EMPOWERCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease	P3	Crohn's Disease	110	Aug 2024
NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	—	Atopic Dermatitis	50	May 2026
NCT07258771	ACUTEUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis	P4	Ulcerative Colitis Acute	110	Jan 2026
NCT06461897	Start UpA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis	P3	Atopic Dermatitis	675	Aug 2024
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	Psoriasis	10	Aug 2026
NCT06012240	Up-AAA Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata	P3	Alopecia Areata	1,500	Oct 2023
NCT07510191	CDTNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response	P4	Crohn Disease (CD)	312	Mar 2026
NCT03358693	MSIDMolecular Signatures in Inflammatory Skin Disease	—	Atopic Dermatitis	300	Jan 2017
NCT05609630	SELECT-sJIAStudy of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	P3	Juvenile Idiopathic Arthritis	90	Oct 2023
NCT06454461	Efficacy of Upadacitinib After NECS in Vitiligo	N/A	Vitiligo	60	Dec 2024
NCT06687551	JAK-TAPJAK Inhibitor Dose TAPering Strategy Study	P4	Rhumatoid Arthisis	308	Jan 2025
NCT07023302	Jump Up AA JPA Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata	P3	Alopecia Areata	123	Jun 2025
NCT07487311	GUSA Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	—	Inflamatory Bowel Disease	80	Jan 2026
NCT06780683	EaseUpIBDEfficacy and Safety of Upadacitinib in Inflammatory Bowel Disease	—	Inflammatory Bowel Disease	174	Jan 2024
NCT06016517	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	—	Arthritis, Rheumatoid	18	May 2026
NCT07550673	Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）	P4	Acute Severe Ulcerative Colitis	226	Apr 2026
NCT06454188	UP-SPOUTA Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis	P4	Psoriatic Arthritis	100	Dec 2024
NCT07502339	Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis	P4	UC - Ulcerative Colitis	50	Jul 2026
NCT07492251	Upa_LPUpadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.	P2	Lichen Penis Planus	56	Jun 2026
NCT06227910	VICTRIVAA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	P3	Crohn's Disease	396	Jan 2025
NCT05889182	Step-Up HSA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	P3	Hidradenitis Suppurativa	1,328	Jun 2023
NCT06928272	LCLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study	P3	Long COVID	348	Sep 2025
NCT07149467	Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study	P3	Crohn's Disease Aggravated	454	Sep 2025
NCT07064889	The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia	P2	Immune Thrombocytopenia	132	Jul 2025
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	Rheumatic Disease	80	Sep 2025
NCT06660693	RESCUE UCComparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis	P3	Colitis, Ulcerative	134	Apr 2025
NCT06862284	Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome	P2	Primary Sjögren's Syndrome (pSS)	30	Mar 2025
NCT06520397	Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease	P4	Crohn Disease	214	Jul 2024
NCT07546097	Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）	P4	Acute Severe Ulcerative Colitis	46	Mar 2026
NCT06684522	Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis	Early P1	Eyelid Dermatitis	10	Dec 2025
NCT07018206	UP-FOR-UImpact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis	P4	Axial Spondylarthritis (axSpA)	200	May 2026
NCT06389136	Switch-UpA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab	P3	Atopic Dermatitis	200	Jun 2024
NCT06873100	Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis	P1/P2	Relapsing Polychondritis	30	Nov 2024
NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	Alopecia Areata	150	Jul 2024
NCT06902987	Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease	P1	Crohn's Diseases	27	Jan 2024
NCT06095596	Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis	N/A	Ulcerative Colitis (UC)	334	Nov 2023
NCT07425899	A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants	P1	Healthy Volunteer	32	Feb 2026
NCT06144567	Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis	—	Psoriatic Arthritis	19	Dec 2023
NCT07442045	Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis	—	Ulcerative Colitis (UC)	150	Jan 2023
NCT05867329	SMARTFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis	P4	Ulcerative Colitis Acute	162	Sep 2023
NCT06630715	OPTIMAEfficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.	—	Rheumatoid Arthritis (RA	178	Jul 2024
NCT06937788	Re-HU-TREATReplication of the Heads Up Atopic Dermatitis Trial With Registry Data	—	Atopic Dermatitis	240	Aug 2021
NCT06498167	LOOK-UPActive Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	—	Inflammatory Disease	150	Jul 2024
NCT06379958	DDIDrug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects	P1	Pharmacokinetics	48	Apr 2024

Upadacitinib clinical trials by indication

Atopic Dermatitis (17)

NCT	Acronym	Phase	Status	Title
NCT07448363	—	N/A	not yet recruiting	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
NCT03568318	AD Up	P3	active not recruiting	A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06461897	Start Up	P3	recruiting	A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT03358693	MSID	N/A	recruiting	Molecular Signatures in Inflammatory Skin Disease
NCT06389136	Switch-Up	P3	recruiting	A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06701331	Start Up Japan	P3	active not recruiting	Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
NCT06390722	Sleep Up	P3	withdrawn	A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
NCT06937788	Re-HU-TREAT	N/A	recruiting	Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
+ 9 more, see All trials below.

Rheumatoid Arthritis (13)

NCT	Acronym	Phase	Status	Title
NCT02629159	SELECT-COMPARE	P3	active not recruiting	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT05814627	SELECT- SWITCH	P3	active not recruiting	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT04530305	MARAJA	N/A	unknown	Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor
NCT05121298	DOPPLER	P3	unknown	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate
NCT05080218	COVER	P4	completed	COVID-19 VaccinE Response in Rheumatology Patients
NCT05153200	—	P4	unknown	Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.
NCT02706873	SELECT-EARLY	P3	completed	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
NCT02706951	ABT-494	P3	completed	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
+ 5 more, see All trials below.

Ulcerative Colitis (UC) (6)

NCT	Acronym	Phase	Status	Title
NCT03006068	U-ACTIVATE	P3	active not recruiting	A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT06095596	—	N/A	recruiting	Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
NCT07442045	—	N/A	recruiting	Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
NCT07472309	—	N/A	completed	Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
NCT02819635	ABT-494	P2/P3	completed	A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT03653026	U-Accomplish	P3	completed	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

Crohn's Disease (5)

NCT	Acronym	Phase	Status	Title
NCT06332534	U-EMPOWER	P3	recruiting	Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06227910	VICTRIVA	P3	recruiting	A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT03345823	U-ENDURE	P3	active not recruiting	A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345849	U-EXCEL	P3	completed	A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
NCT03345836	ABT-494	P3	completed	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Psoriatic Arthritis (4)

NCT	Acronym	Phase	Status	Title
NCT06454188	UP-SPOUT	P4	recruiting	A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06144567	—	N/A	not yet recruiting	Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis
NCT03104374	SELECT - PsA 2	P3	completed	A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
NCT03104400	SELECT - PsA 1	P3	completed	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Rheumatoid Arthritis (RA) (4)

NCT	Acronym	Phase	Status	Title
NCT03086343	—	P3	completed	A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
NCT03823378	—	P2	terminated	A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
NCT02955212	ABT-494	P3	completed	A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
NCT03682705	—	P2	completed	A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Alopecia Areata (3)

NCT	Acronym	Phase	Status	Title
NCT06012240	Up-AA	P3	recruiting	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT07023302	Jump Up AA JP	P3	recruiting	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
NCT06573593	—	N/A	recruiting	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Acute Severe Ulcerative Colitis (2)

NCT	Acronym	Phase	Status	Title
NCT07550673	—	P4	recruiting	Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
NCT07546097	—	P4	recruiting	Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）

Ulcerative Colitis Acute (2)

NCT	Acronym	Phase	Status	Title
NCT07258771	ACUTE	P4	recruiting	Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
NCT05867329	SMART	P4	recruiting	Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Vitiligo (2)

NCT	Acronym	Phase	Status	Title
NCT06454461	—	N/A	recruiting	Efficacy of Upadacitinib After NECS in Vitiligo
NCT06118411	Viti-Up	P3	active not recruiting	A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

Crohn Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06520397	—	P4	recruiting	Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
NCT04159597	—	N/A	available	Expanded Access to Upadacitinib

Systemic Lupus Erythematosus (SLE) (2)

NCT	Acronym	Phase	Status	Title
NCT04451772	ABBV-599	P2	completed	A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
NCT03978520	SLEek	P2	completed	A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

UC - Ulcerative Colitis (1)

NCT	Acronym	Phase	Status	Title
NCT07502339	—	P4	not yet recruiting	Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

Lichen Penis Planus (1)

NCT	Acronym	Phase	Status	Title
NCT07492251	Upa_LP	P2	not yet recruiting	Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.

Axial Spondylarthritis (axSpA) (1)

NCT	Acronym	Phase	Status	Title
NCT07018206	UP-FOR-U	P4	not yet recruiting	Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

Arthritis, Rheumatoid (1)

NCT	Acronym	Phase	Status	Title
NCT06016517	—	N/A	not yet recruiting	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Crohn Disease (CD) (1)

NCT	Acronym	Phase	Status	Title
NCT07510191	CD	P4	recruiting	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

Healthy Volunteer (1)

NCT	Acronym	Phase	Status	Title
NCT07425899	—	P1	recruiting	A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Inflamatory Bowel Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07487311	GUS	N/A	recruiting	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT07352566	—	P4	not yet recruiting	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Rheumatic Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07138898	—	P2	not yet recruiting	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Long COVID (1)

NCT	Acronym	Phase	Status	Title
NCT06928272	LC	P3	recruiting	Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

Crohn's Disease Aggravated (1)

NCT	Acronym	Phase	Status	Title
NCT07149467	—	P3	not yet recruiting	Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

Immune Thrombocytopenia (1)

NCT	Acronym	Phase	Status	Title
NCT07064889	—	P2	not yet recruiting	The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Moderate to Severe Rheumatoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT07008846	—	P3	active not recruiting	Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

Colitis, Ulcerative (1)

NCT	Acronym	Phase	Status	Title
NCT06660693	RESCUE UC	P3	recruiting	Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

Primary Sjögren's Syndrome (pSS) (1)

NCT	Acronym	Phase	Status	Title
NCT06862284	—	P2	not yet recruiting	Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Rhumatoid Arthisis (1)

NCT	Acronym	Phase	Status	Title
NCT06687551	JAK-TAP	P4	not yet recruiting	JAK Inhibitor Dose TAPering Strategy Study

Eyelid Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT06684522	—	Early P1	recruiting	Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

Relapsing Polychondritis (1)

NCT	Acronym	Phase	Status	Title
NCT06873100	—	P1/P2	recruiting	Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Rheumatoid Arthritis (RA (1)

NCT	Acronym	Phase	Status	Title
NCT06630715	OPTIMA	N/A	recruiting	Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.

Inflammatory Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06498167	LOOK-UP	N/A	recruiting	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Prurigo Nodularis (1)

NCT	Acronym	Phase	Status	Title
NCT06773403	—	P4	terminated	Upadacitinib for Prurigo Nodularis

Pharmacokinetics (1)

NCT	Acronym	Phase	Status	Title
NCT06379958	DDI	P1	recruiting	Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Behcet Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT07080346	—	P2	completed	Upadacitinib for Refractory Behcet's Syndrome

Crohn's Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT06902987	—	P1	recruiting	Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease

Inflammatory Bowel Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06780683	EaseUpIBD	N/A	recruiting	Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Ulcerative Colitis (1)

NCT	Acronym	Phase	Status	Title
NCT05782907	U-ASTOUND	P3	active not recruiting	Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Juvenile Idiopathic Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT05609630	SELECT-sJIA	P3	recruiting	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Systemic Lupus Erythematosus (1)

NCT	Acronym	Phase	Status	Title
NCT05843643	SELECT-SLE	P3	active not recruiting	Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Hidradenitis Suppurativa (1)

NCT	Acronym	Phase	Status	Title
NCT05889182	Step-Up HS	P3	recruiting	A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Interstitial Lung Disease Due to Systemic Disease (Disorder) (1)

NCT	Acronym	Phase	Status	Title
NCT06758947	upadacetinib	P3	completed	Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

Crohn's Disease (CD) (1)

NCT	Acronym	Phase	Status	Title
NCT06922331	UPA-AGE	N/A	completed	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis

Axial Spondylarthritis (r-axSpA) (1)

NCT	Acronym	Phase	Status	Title
NCT05094128	UpSPINE	N/A	active not recruiting	A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

Non-Segmental Vitiligo (1)

NCT	Acronym	Phase	Status	Title
NCT04927975	—	P2	completed	Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Inflammatory Bowel Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT06274996	—	N/A	completed	Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease

Atopic Dermatitis (AD) (1)

NCT	Acronym	Phase	Status	Title
NCT04666675	—	P3	withdrawn	A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

Hidradenitis Suppurativa (HS) (1)

NCT	Acronym	Phase	Status	Title
NCT04430855	—	P2	completed	A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Takayasu Arteritis (TAK) (1)

NCT	Acronym	Phase	Status	Title
NCT04161898	SELECT-TAK	P3	active not recruiting	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

Spondyloarthritis (1)

NCT	Acronym	Phase	Status	Title
NCT04169373	SELECT-AXIS 2	P3	completed	A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

Juvenile Idiopathic Arthritis (JIA) (1)

NCT	Acronym	Phase	Status	Title
NCT03725007	SELECT-YOUTH	P1	active not recruiting	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

Giant Cell Arteritis (GCA) (1)

NCT	Acronym	Phase	Status	Title
NCT03725202	SELECT-GCA	P3	completed	A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Ankylosing Spondylitis (AS) (1)

NCT	Acronym	Phase	Status	Title
NCT03178487	SELECT-AXIS 1	P2	completed	A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Upadacitinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
ACUTE	NCT07258771	P4	recruiting	Ulcerative Colitis Acute	110	—
CD	NCT07510191	P4	recruiting	Crohn Disease (CD)	312	—
JAK-TAP	NCT06687551	P4	not yet recruiting	Rhumatoid Arthisis	308	—
UP-SPOUT	NCT06454188	P4	recruiting	Psoriatic Arthritis	100	—
UP-FOR-U	NCT07018206	P4	not yet recruiting	Axial Spondylarthritis (axSpA)	200	—
SMART	NCT05867329	P4	recruiting	Ulcerative Colitis Acute	162	—
Flex-Up	NCT05507580	P4	completed	Atopic Dermatitis	461	—
COVER	NCT05080218	P4	completed	Rheumatoid Arthritis	841	—
U-EMPOWER	NCT06332534	P3	recruiting	Crohn's Disease	110	—
U-ASTOUND	NCT05782907	P3	active not recruiting	Ulcerative Colitis	122	—
AD Up	NCT03568318	P3	active not recruiting	Atopic Dermatitis	1,533	PMID 36333616
Start Up	NCT06461897	P3	recruiting	Atopic Dermatitis	675	—
Up-AA	NCT06012240	P3	recruiting	Alopecia Areata	1,500	—
SELECT-sJIA	NCT05609630	P3	recruiting	Juvenile Idiopathic Arthritis	90	—
Jump Up AA JP	NCT07023302	P3	recruiting	Alopecia Areata	123	—
SELECT-TAK	NCT04161898	P3	active not recruiting	Takayasu Arteritis (TAK)	56	—
VICTRIVA	NCT06227910	P3	recruiting	Crohn's Disease	396	PMID 41403476
Viti-Up	NCT06118411	P3	active not recruiting	Vitiligo	614	—
Step-Up HS	NCT05889182	P3	recruiting	Hidradenitis Suppurativa	1,328	—
LC	NCT06928272	P3	recruiting	Long COVID	348	—
SELECT-SLE	NCT05843643	P3	active not recruiting	Systemic Lupus Erythematosus	1,014	—
RESCUE UC	NCT06660693	P3	recruiting	Colitis, Ulcerative	134	—
U-ENDURE	NCT03345823	P3	active not recruiting	Crohn's Disease	747	PMID 41264726
SELECT-COMPARE	NCT02629159	P3	active not recruiting	Rheumatoid Arthritis	1,629	PMID 33590829
U-ACTIVATE	NCT03006068	P3	active not recruiting	Ulcerative Colitis (UC)	950	PMID 40347957
Switch-Up	NCT06389136	P3	recruiting	Atopic Dermatitis	200	—
Start Up Japan	NCT06701331	P3	active not recruiting	Atopic Dermatitis	99	—
SELECT- SWITCH	NCT05814627	P3	active not recruiting	Rheumatoid Arthritis	487	PMID 41991443
Sleep Up	NCT06390722	P3	withdrawn	Atopic Dermatitis	0	—
Measure Up 1	NCT03569293	P3	completed	Atopic Dermatitis	912	PMID 37247226
SELECT-GCA	NCT03725202	P3	completed	Giant Cell Arteritis (GCA)	429	PMID 38840219
SELECT-AXIS 2	NCT04169373	P3	completed	Spondyloarthritis	734	PMID 41039829
upadacetinib	NCT06758947	P3	completed	Interstitial Lung Disease Due to Systemic Disease (Disorder)	60	—
DOPPLER	NCT05121298	P3	unknown	Rheumatoid Arthritis	155	PMID 35029189
SELECT - PsA 2	NCT03104374	P3	completed	Psoriatic Arthritis	642	PMID 34661885
SELECT - PsA 1	NCT03104400	P3	completed	Psoriatic Arthritis	1,705	PMID 34636026
Level Up	NCT05601882	P3	completed	Atopic Dermatitis	920	PMID 41533220
SELECT-EARLY	NCT02706873	P3	completed	Rheumatoid Arthritis	1,002	PMID 39075620
Rising Up	NCT03661138	P3	completed	Atopic Dermatitis	272	PMID 36185549
ABT-494	NCT02706951	P3	completed	Rheumatoid Arthritis	648	PMID 34041702
SELECT-NEXT	NCT02675426	P3	completed	Rheumatoid Arthritis	661	PMID 31815649
SELECT-BEYOND	NCT02706847	P3	completed	Rheumatoid Arthritis	499	PMID 39053948
U-EXCEL	NCT03345849	P3	completed	Crohn's Disease	526	PMID 38492904
ABT-494	NCT03345836	P3	completed	Crohn's Disease	624	PMID 39326583
U-Accomplish	NCT03653026	P3	completed	Ulcerative Colitis (UC)	522	PMID 37942921
Heads Up	NCT03738397	P3	completed	Atopic Dermatitis	673	PMID 34347860
ABT-494	NCT02955212	P3	completed	Rheumatoid Arthritis (RA)	338	—
Upa_LP	NCT07492251	P2	not yet recruiting	Lichen Penis Planus	56	—
ABBV-599	NCT04451772	P2	completed	Systemic Lupus Erythematosus (SLE)	185	—
SLEek	NCT03978520	P2	completed	Systemic Lupus Erythematosus (SLE)	341	PMID 33687069
SELECT-AXIS 1	NCT03178487	P2	completed	Ankylosing Spondylitis (AS)	187	PMID 34196498
BALANCE-EXTEND	NCT02049138	P2	completed	Rheumatoid Arthritis	493	PMID 35246470
ABT-494	NCT02066389	P2	completed	Rheumatoid Arthritis	300	PMID 31194885

Terminated and withdrawn Upadacitinib trials (4)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06390722withdrawnA Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
NCT06773403terminatedUpadacitinib for Prurigo Nodularis
NCT04666675withdrawnA Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
NCT03823378terminatedA Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

All Upadacitinib trials (103)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06332534	U-EMPOWER	Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease	P3	recruiting	110	AbbVie	Aug 2024
NCT05782907	U-ASTOUND	Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.	P3	active not recruiting	122	AbbVie	Nov 2023
NCT07448363		Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	—	not yet recruiting	50	Caja Costarricense de Seguro Social	May 2026
NCT07258771	ACUTE	Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis	P4	recruiting	110	Berinstein, Jeffrey	Jan 2026
NCT03568318	AD Up	A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	P3	active not recruiting	1,533	AbbVie	Aug 2018
NCT06461897	Start Up	A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis	P3	recruiting	675	AbbVie	Aug 2024
NCT07352566		Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	not yet recruiting	10	University of California, San Francisco	Aug 2026
NCT06012240	Up-AA	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata	P3	recruiting	1,500	AbbVie	Oct 2023
NCT07510191	CD	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response	P4	recruiting	312	Sixth Affiliated Hospital, Sun Yat-sen University	Mar 2026
NCT03358693	MSID	Molecular Signatures in Inflammatory Skin Disease	—	recruiting	300	Prof. Dr. Stephan Weidinger	Jan 2017
NCT05609630	SELECT-sJIA	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	P3	recruiting	90	AbbVie	Oct 2023
NCT06454461		Efficacy of Upadacitinib After NECS in Vitiligo	N/A	recruiting	60	Jilin University	Dec 2024
NCT06687551	JAK-TAP	JAK Inhibitor Dose TAPering Strategy Study	P4	not yet recruiting	308	University Hospital, Toulouse	Jan 2025
NCT07023302	Jump Up AA JP	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata	P3	recruiting	123	AbbVie	Jun 2025
NCT07487311	GUS	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	—	recruiting	80	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2026
NCT06780683	EaseUpIBD	Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease	—	recruiting	174	Xiang Gao	Jan 2024
NCT06016517		Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	—	not yet recruiting	18	Tufts Medical Center	May 2026
NCT07550673		Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）	P4	recruiting	226	Xijing Hospital of Digestive Diseases	Apr 2026
NCT06454188	UP-SPOUT	A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis	P4	recruiting	100	CARE ARTHRITIS LTD.	Dec 2024
NCT04161898	SELECT-TAK	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)	P3	active not recruiting	56	AbbVie	Feb 2020
NCT07502339		Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis	P4	not yet recruiting	50	University of California, San Francisco	Jul 2026
NCT07492251	Upa_LP	Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.	P2	not yet recruiting	56	Centre Hospitalier Universitaire de Nice	Jun 2026
NCT06227910	VICTRIVA	A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	P3	recruiting	396	Takeda	Jan 2025
NCT06118411	Viti-Up	A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo	P3	active not recruiting	614	AbbVie	Dec 2023
NCT05889182	Step-Up HS	A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	P3	recruiting	1,328	AbbVie	Jun 2023
NCT06928272	LC	Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study	P3	recruiting	348	Douglas D. Fraser	Sep 2025
NCT07149467		Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study	P3	not yet recruiting	454	Sixth Affiliated Hospital, Sun Yat-sen University	Sep 2025
NCT07064889		The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia	P2	not yet recruiting	132	Peking University People's Hospital	Jul 2025
NCT05843643	SELECT-SLE	Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus	P3	active not recruiting	1,014	AbbVie	Jul 2023
NCT07138898		Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	not yet recruiting	80	NYU Langone Health	Sep 2025
NCT06660693	RESCUE UC	Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis	P3	recruiting	134	McMaster University	Apr 2025
NCT03345823	U-ENDURE	A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433	P3	active not recruiting	747	AbbVie	Mar 2018
NCT02629159	SELECT-COMPARE	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	P3	active not recruiting	1,629	AbbVie	Dec 2015
NCT06862284		Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome	P2	not yet recruiting	30	Peking University People's Hospital	Mar 2025
NCT06520397		Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease	P4	recruiting	214	Sixth Affiliated Hospital, Sun Yat-sen University	Jul 2024
NCT03006068	U-ACTIVATE	A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)	P3	active not recruiting	950	AbbVie	Jan 2017
NCT07546097		Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）	P4	recruiting	46	Yongquan Shi	Mar 2026
NCT06684522		Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis	Early P1	recruiting	10	Northwestern University	Dec 2025
NCT07018206	UP-FOR-U	Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis	P4	not yet recruiting	200	CARE ARTHRITIS LTD.	May 2026
NCT03725007	SELECT-YOUTH	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis	P1	active not recruiting	124	AbbVie	Jun 2019
NCT05094128	UpSPINE	A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting	—	active not recruiting	338	AbbVie	Nov 2021
NCT06389136	Switch-Up	A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab	P3	recruiting	200	AbbVie	Jun 2024
NCT06701331	Start Up Japan	Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis	P3	active not recruiting	99	AbbVie	Dec 2024
NCT06873100		Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis	P1/P2	recruiting	30	Peking University People's Hospital	Nov 2024
NCT06573593		Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	recruiting	150	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jul 2024
NCT06902987		Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease	P1	recruiting	27	Sixth Affiliated Hospital, Sun Yat-sen University	Jan 2024
NCT06095596		Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis	N/A	recruiting	334	Sixth Affiliated Hospital, Sun Yat-sen University	Nov 2023
NCT07008846		Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis	P3	active not recruiting	96	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	May 2025
NCT07425899		A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants	P1	recruiting	32	AbbVie	Feb 2026
NCT05814627	SELECT- SWITCH	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis	P3	active not recruiting	487	AbbVie	Jun 2023
NCT06390722	Sleep Up	A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis	P3	withdrawn	0	AbbVie	May 2024
NCT06144567		Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis	—	not yet recruiting	19	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz	Dec 2023
NCT07442045		Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis	—	recruiting	150	Sixth Affiliated Hospital, Sun Yat-sen University	Jan 2023
NCT05867329	SMART	Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis	P4	recruiting	162	Berinstein, Jeffrey	Sep 2023
NCT07472309		Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis	—	completed	81	Xijing Hospital of Digestive Diseases	Jun 2023
NCT06630715	OPTIMA	Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.	—	recruiting	178	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	Jul 2024
NCT06937788	Re-HU-TREAT	Replication of the Heads Up Atopic Dermatitis Trial With Registry Data	—	recruiting	240	Technische Universität Dresden	Aug 2021
NCT03607422		A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)	P3	completed	912	AbbVie	Jul 2018
NCT03569293	Measure Up 1	Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)	P3	completed	912	AbbVie	Aug 2018
NCT07080346		Upadacitinib for Refractory Behcet's Syndrome	P2	completed	27	Liu Tian	Jan 2024
NCT06773403		Upadacitinib for Prurigo Nodularis	P4	terminated	5	Psoriasis Treatment Center of Central New Jersey	Apr 2024
NCT03725202	SELECT-GCA	A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis	P3	completed	429	AbbVie	Jan 2019
NCT06922331	UPA-AGE	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	—	completed	21	Sixth Affiliated Hospital, Sun Yat-sen University	Jan 2023
NCT04169373	SELECT-AXIS 2	A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis	P3	completed	734	AbbVie	Nov 2019
NCT06498167	LOOK-UP	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	—	recruiting	150	Universidade do Porto	Jul 2024
NCT06758947	upadacetinib	Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	P3	completed	60	Assiut University	Jan 2023
NCT04530305	MARAJA	Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor	—	unknown	60	University Hospital, Montpellier	Jan 2021
NCT06379958	DDI	Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects	P1	recruiting	48	Modern Biosciences Ltd	Apr 2024
NCT05121298	DOPPLER	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	P3	unknown	155	Atsushi Kawakami	Jan 2021
NCT03104374	SELECT - PsA 2	A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug	P3	completed	642	AbbVie	May 2017
NCT03104400	SELECT - PsA 1	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)	P3	completed	1,705	AbbVie	Apr 2017
NCT03646604		A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis	P1	completed	35	AbbVie	Jan 2019
NCT05507580	Flex-Up	A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis	P4	completed	461	AbbVie	May 2023
NCT05601882	Level Up	A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	920	AbbVie	Nov 2022
NCT05080218	COVER	COVID-19 VaccinE Response in Rheumatology Patients	P4	completed	841	Jeffrey Curtis	Nov 2021
NCT04451772	ABBV-599	A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State	P2	completed	185	AbbVie	Jul 2020
NCT06274996		Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease	—	completed	81	Sixth Affiliated Hospital, Sun Yat-sen University	Jan 2021
NCT04195698		Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	475	AbbVie	Jan 2020
NCT04927975		Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo	P2	completed	185	AbbVie	Jun 2021
NCT05153200		Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.	P4	unknown	40	Ottawa Hospital Research Institute	Jan 2022
NCT03086343		A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs	P3	completed	657	AbbVie	May 2017
NCT02706873	SELECT-EARLY	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	P3	completed	1,002	AbbVie	Feb 2016
NCT03661138	Rising Up	A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	272	AbbVie	Oct 2018
NCT02706951	ABT-494	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	P3	completed	648	AbbVie	Mar 2016
NCT03978520	SLEek	A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)	P2	completed	341	AbbVie	Jul 2019
NCT02720523	SELECTSUNRISE	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	P2/P3	completed	197	AbbVie	Mar 2016
NCT02675426	SELECT-NEXT	A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	P3	completed	661	AbbVie	Dec 2015
NCT03178487	SELECT-AXIS 1	A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis	P2	completed	187	AbbVie	Oct 2017
NCT02706847	SELECT-BEYOND	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs	P3	completed	499	AbbVie	Mar 2016
NCT04430855		A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms	P2	completed	68	AbbVie	Jul 2020
NCT03345849	U-EXCEL	A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies	P3	completed	526	AbbVie	Dec 2017
NCT02819635	ABT-494	A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)	P2/P3	completed	1,302	AbbVie	Sep 2016
NCT03345836	ABT-494	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy	P3	completed	624	AbbVie	Nov 2017
NCT02049138	BALANCE-EXTEND	An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis	P2	completed	493	AbbVie	Jan 2014
NCT04666675		A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	P3	withdrawn	0	AbbVie	Dec 2020
NCT03653026	U-Accomplish	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis	P3	completed	522	AbbVie	Dec 2018
NCT03738397	Heads Up	A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	673	AbbVie	Feb 2019
NCT03823378		A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib	P2	terminated	97	AbbVie	May 2019
NCT02955212	ABT-494	A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	P3	completed	338	AbbVie	Jan 2018
NCT03682705		A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis	P2	completed	242	AbbVie	Oct 2018
NCT04159597		Expanded Access to Upadacitinib	—	available	0	AbbVie	—
NCT02925117		A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis	P2	completed	167	AbbVie	Oct 2016
NCT02066389	ABT-494	A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone	P2	completed	300	AbbVie	Mar 2014

Upadacitinib clinical trials: frequently asked questions

How many Upadacitinib clinical trials are there?: 103 Upadacitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 32 are actively recruiting participants. 38 are marked completed.
Are Upadacitinib clinical trials recruiting in 2026?: Yes — 32 Upadacitinib trials are actively recruiting in 2026, with 225 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Upadacitinib being studied for?: Upadacitinib is being studied for Atopic Dermatitis, Rheumatoid Arthritis, Ulcerative Colitis (UC), Crohn's Disease, Psoriatic Arthritis and 74 more. The trials are grouped by indication on this page.
What phase is Upadacitinib in?: Upadacitinib clinical trials span 15 Phase 4, 45 Phase 3, 15 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Upadacitinib clinical trials?: The lead sponsor across the most Upadacitinib trials is AbbVie, with 33 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Upadacitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Upadacitinib overview Upadacitinib evidence & publications